Protara Therapeutics, Inc. (TARA)
NASDAQ
Closed
Oct 15, 2026
Day's Range
2.4852 wk Range
2.47Overview - TARA - Protara Therapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
54.08M
P/E (Trailing)
-2.44
P/E (Forward)
-1.93
PEG Ratio
-0.85
Price / Book
1.20
EV / EBITDA
-0.70
Profitability
Profit Margin
0.00%
Operating Margin
0.00%
Return on Assets
-28.82%
Return on Equity
-45.80%
Ownership
Shares Outstanding
59.08M
Float
54.88M
Short % of Shares Outstanding
7.60%
Held by Insiders
2.30%
Held by Institutions
78.38%
Price stats
Beta
1.48
50-Day Avg
3.90
200-Day Avg
4.93
Dividends
Payout Ratio
0.00%
Analyst Consensus
8 analysts
Shariah Compliance
Report Date: Feb 16, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - TARA - Protara Therapeutics, Inc.
Peers - TARA - Protara Therapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- TARANASDAQProtara Therapeutics, Inc.193.83MMarket Cap-34.45%52-week change-2.44P/E (Trailing)0.00%Profit Margin
- ARGXNASDAQArgenx SE54.66BMarket Cap+4.54%52-week change30.26P/E (Trailing)31.73%Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.29.97BMarket Cap-110.32%52-week change37.78P/E (Trailing)16.12%Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.13BMarket Cap-20.35%52-week change160.80P/E (Trailing)-63.63%Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.01BMarket Cap+16.49%52-week change18.23P/E (Trailing)70.84%Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)-97.02%Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.58BMarket Cap+1.57%52-week change147.76P/E (Trailing)2.14%Profit Margin
Profile Summary - TARA - Protara Therapeutics, Inc.
About
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its current pipeline centers on TARA-002, an investigational cell therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, and intravenous choline…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
